Publications

Highlighted Publications

1. Yang F, Wynn DT, Shen C, Ayad NG, Robbins DJ. Multiprotein GLI Transcriptional Complexes as Therapeutic Targets in Cancer. Life. 2022; 12(12):1967. 

2. Wynn DT, Rodriguez-Blanco J, Long J, Yang F, Shen C, Fei D, Tang HY, Hanson D, Robbins DJ. Protein arginine methyltransferase 5 regulates SHH-subgroup medulloblastoma progression. Neurooncol Adv. 2022 Sep 29;4(1):vdac144. doi: 10.1093/noajnl/vdac144. 

3. Yang F, Rodriguez-Blanco J, Long J, Swiderska-Syn M, Wynn DT, Li B, Shen C, Nayak A, Ban Y, Sun X, Suter RK, McCrea HJ, Capobianco AJ, Ayad NG, Robbins DJ. A druggable UHRF1/DNMT1/GLI complex regulates Sonic hedgehog dependent tumor growth. Mol Cancer Res. 2022 Aug 4:MCR-22-0182. doi: 10.1158/1541-7786.MCR-22-0182.

4. Shen C, Nayak A, Neitzel LR, Yang F, Li B, Williams CH, Hong CC, Ahmed Y, Lee E, Robbins DJ. The Casein kinase 1α agonist pyrvinium attenuates Wnt-mediated CK1α degradation via interaction with the E3 ubiquitin ligase component Cereblon. J Biol Chem. 2022 Aug;298(8):102227. doi: 10.1016/j.jbc.2022.102227. 

5. Shen C, Nayak A, Neitzel LR, Adams AA, Silver-Isenstadt M, Sawyer LM, Benchabane H, Wang H, Bunnag N, Li B, Wynn DT, Yang F, Garcia-Contreras M, Williams C, Dakshanamurthy S, Hong C, Ayad N, Capobianco A, Ahmed Y, Lee E, Robbins DJ. The E3 ubiquitin ligase component, Cereblon, is an evolutionarily conserved regulator of Wnt signaling. Nature Communications. 2021 Sep 6;12(1), 5263, doi:10.1038/s41467-021-25634-z.

6. Penas C, Maloof ME, Stathias V, Long J, Tan SK, Mier J, Fang Y, Valdes C, Rodriguez-Blanco J, Chiang CM, Robbins DJ, Liebl DJ, Lee JK, Hatten ME, Clarke J, Ayad NG. Time-series modeling of cell cycle exit identifies Brd4-dependent regulation of cerebellar neurogenesis. Nature Communications. 2019 Jul 10;10(1):3028. doi: 10.1038/s41467-019-10799-5.

7. Rodriguez-Blanco J, Li B, Long J, Shen C, Yang F, Orton D, Collins S, Kasahara N, Ayad NG, McCrea HJ, Roussel MF, Weiss WA, Capobianco AJ, Robbins DJ. A CK1α activator penetrates the brain and shows efficacy against drug-resistant metastatic medulloblastoma. Clin Cancer Res. 2019 Feb 15;25(4):1379-1388. doi: 10.1158/1078-0432.CCR-18-1319.

8. Saito-Diaz K, Benchabane H, Ajit T, Tian A, Li B, Thompson JJ, Hyde AS, Sawyer LM, Jodoin JN, Santos E, Lee LA, Coffey RJ, Beauchamp RD, Williams CS, Kenworthy A, Robbins DJ, Ahmed Y, and Lee E. APC inhibits ligand-independent Wnt signaling by the clathrin endocytic pathway. Dev Cell. 2018 Mar 12;12;44(5):566-581.e8. doi: 10.1016/j.devcel.2018.02.013.

9. Rodriguez-Blanco J, Pednekar L, Penas C, Li B, Martin V, Long J, Lee E, Weiss WA, Rodriguez C, Mehrdad N, Nguyen DM, Ayad NG, Rai P, Capobianco AJ, Robbins DJ. Inhibition of WNT signaling attenuates self-renewal of SHH-subgroup medulloblastoma. Oncogene. 2017 Nov 9;36(45):6306-6314. doi: 10.1038/onc.2017.232.

10. Li B, Orton D, Neitzel LR,  Astudillo L, Shen C,  Long J,  Chen X, Kirkbride KC,  Doundoulakis T,  Guerra ML,  Zaias J,  Fei DL,  Rodriguez-Blanco J,  Thorne C,  Wang Z,  Jin K,  Nguyen DM, Sands LR,  Marchetti F,  Abreu MT,  Cobb MH,  Capobianco AJ,  Lee E,  Robbins DJ. Differential abundance of CK1α provides selectivity for pharmacological CK1α activators to target WNT-dependent tumors. Science Signaling. 2017 Jun 27;10(485). pii: eaak9916. doi: 10.1126/scisignal.aak9916.